ADIPOQ and systemic sclerosis: Taken together, these findings implicate adiponectin deficiency as a pathogenic driver of persistent skin fibrosis, and provide evidence that restoring adiponectin signaling may represent a promising novel therapeutic strategy for mitigating fibrosis in SSc.